Key facts
- It has raised $10.0M; the latest was Later Stage VC ($10.0M) in Jan 2025.
- Notable investors include 369 Global, Capital BioVentures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for JN Nova
- ·The full record, as it builds
Funding rounds
No funding rounds for JN Nova are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About JN Nova
Developer of biopharmaceutical products intended to address unmet medical needs. The company's platform uses innovative technologies to develop novel treatments for COVID-19 with potential applications in cardio-pulmonary and neuro-inflammatory indications, enabling patients to access more effective and affordable therapies.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2020
- Employees
- 3
- Website
- jnnova.com/
- Ownership
- Privately Held (backing)
JN Nova doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in JN Nova shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on JN Nova in its N-PORT filings yet. We sweep new filings monthly.